Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C20H28O2 |
Molecular Weight | 300.4351 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 6 / 6 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[H][C@@]12CC[C@](C)(O)[C@@]1(C)CC[C@@]3([H])[C@@]2([H])CCC4=CC(=O)C=C[C@]34C
InChI
InChIKey=XWALNWXLMVGSFR-HLXURNFRSA-N
InChI=1S/C20H28O2/c1-18-9-6-14(21)12-13(18)4-5-15-16(18)7-10-19(2)17(15)8-11-20(19,3)22/h6,9,12,15-17,22H,4-5,7-8,10-11H2,1-3H3/t15-,16+,17+,18+,19+,20+/m1/s1
Molecular Formula | C20H28O2 |
Molecular Weight | 300.4351 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 6 / 6 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
DescriptionSources: https://www.steroidal.com/steroid-profiles/dianabol/Curator's Comment: description was created based on several sources, including:
Lenehan, P. (2003) "Anabolic steroids", p.101 Retrieved from https://books.google.ru/books?id=TOePv6WpruQC | https://www.healthydietadvisor.com/bodybuilding-supplements/dianabol-review/
Sources: https://www.steroidal.com/steroid-profiles/dianabol/
Curator's Comment: description was created based on several sources, including:
Lenehan, P. (2003) "Anabolic steroids", p.101 Retrieved from https://books.google.ru/books?id=TOePv6WpruQC | https://www.healthydietadvisor.com/bodybuilding-supplements/dianabol-review/
Metandienone is an orally active synthetic anabolic-androgenic steroid. In 1970, the FDA accepted that Metandienone (Dianabol) was “Probably Effective” in treating post-menopausal osteoporosis and pituitary-deficient dwarfism. Methandrostenolone is still produced today, but typically in nations with loose prescription drug regulations and by companies that still prefer to cater to an underground athletic market. Androgenic side effects are still common with this substance. This may include bouts of oily skin, acne, and body/facial hair growth. Anabolic/androgenic steroids may also aggravate male pattern hair loss.
CNS Activity
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL3072 Sources: https://www.ncbi.nlm.nih.gov/pubmed/9593936 |
|||
Target ID: CHEMBL3859 Sources: https://www.ncbi.nlm.nih.gov/pubmed/9593936 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Dianabol Approved UseIt is indicated for the treatment of post-menopausal osteoporosis and pituitary-deficient dwarfism. |
|||
Primary | Dianabol Approved UseIt is indicated for the treatment of post-menopausal osteoporosis and pituitary-deficient dwarfism. |
Doses
Dose | Population | Adverse events |
---|---|---|
15 mg 1 times / day multiple, oral Dose: 15 mg, 1 times / day Route: oral Route: multiple Dose: 15 mg, 1 times / day Sources: |
healthy, 20-48 years n = 15 Health Status: healthy Age Group: 20-48 years Sex: M Population Size: 15 Sources: |
Disc. AE: Infertility... AEs leading to discontinuation/dose reduction: Infertility (15 patients) Sources: |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Infertility | 15 patients Disc. AE |
15 mg 1 times / day multiple, oral Dose: 15 mg, 1 times / day Route: oral Route: multiple Dose: 15 mg, 1 times / day Sources: |
healthy, 20-48 years n = 15 Health Status: healthy Age Group: 20-48 years Sex: M Population Size: 15 Sources: |
PubMed
Title | Date | PubMed |
---|---|---|
Bleeding oesophageal varices associated with anabolic steroid use in an athlete. | 1990 Oct |
|
[Experimental study of pharmacotherapeutic effect of phytoecdisteroids and nerobol in toxic liver damage]. | 2001 Jul-Aug |
|
Practical uses for ecdysteroids in mammals including humans: an update. | 2003 |
|
[Hepatoprotective effects of silymarin in androgenic-anabolic steroid-induced liver damage]. | 2003 |
|
Glucuronidation of anabolic androgenic steroids by recombinant human UDP-glucuronosyltransferases. | 2003 Sep |
|
[Assessment of mutagenic danger of food products]. | 2004 |
|
[Acute myocardial infarction in a young man who had been using androgenic anabolic steroids]. | 2004 Jan 22 |
|
Validation of a GC-MS screening method for anabolizing agents in aqueous nutritional supplements. | 2005 Jan |
|
[Main symptom jaundice--differential diagnosis at the bedside]. | 2007 Jan 15 |
|
Detection of urinary metabolites common to structurally related 17alpha-alkyl anabolic steroids in horses and application to doping tests in racehorses: methandienone, methandriol, and oxymetholone. | 2008 Jun |
|
uPA+/+-SCID mouse with humanized liver as a model for in vivo metabolism of exogenous steroids: methandienone as a case study. | 2009 Oct |
|
Feasibility of capillary liquid chromatography/microchip atmospheric pressure photoionization mass spectrometry in analyzing anabolic steroids in urine samples. | 2010 Apr 15 |
Patents
Sample Use Guides
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/23675320
Cell death was evaluated by staining PC12 cells treated for 48 h with 75 uM methandienone. Methandienone is toxic to neurons, inducing death in treated cells.
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 14:58:18 GMT 2023
by
admin
on
Fri Dec 15 14:58:18 GMT 2023
|
Record UNII |
COZ1R7EOCC
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Official Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
WHO-VATC |
QA14AA03
Created by
admin on Fri Dec 15 14:58:19 GMT 2023 , Edited by admin on Fri Dec 15 14:58:19 GMT 2023
|
||
|
DEA NO. |
4000
Created by
admin on Fri Dec 15 14:58:19 GMT 2023 , Edited by admin on Fri Dec 15 14:58:19 GMT 2023
|
||
|
WHO-ATC |
A14AA03
Created by
admin on Fri Dec 15 14:58:19 GMT 2023 , Edited by admin on Fri Dec 15 14:58:19 GMT 2023
|
||
|
WHO-ATC |
D11AE01
Created by
admin on Fri Dec 15 14:58:19 GMT 2023 , Edited by admin on Fri Dec 15 14:58:19 GMT 2023
|
||
|
LIVERTOX |
613
Created by
admin on Fri Dec 15 14:58:19 GMT 2023 , Edited by admin on Fri Dec 15 14:58:19 GMT 2023
|
||
|
WIKIPEDIA |
Designer-drugs-Methandrostenolone
Created by
admin on Fri Dec 15 14:58:19 GMT 2023 , Edited by admin on Fri Dec 15 14:58:19 GMT 2023
|
||
|
NCI_THESAURUS |
C2360
Created by
admin on Fri Dec 15 14:58:19 GMT 2023 , Edited by admin on Fri Dec 15 14:58:19 GMT 2023
|
||
|
WHO-VATC |
QD11AE01
Created by
admin on Fri Dec 15 14:58:19 GMT 2023 , Edited by admin on Fri Dec 15 14:58:19 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
1734
Created by
admin on Fri Dec 15 14:58:19 GMT 2023 , Edited by admin on Fri Dec 15 14:58:19 GMT 2023
|
PRIMARY | |||
|
72-63-9
Created by
admin on Fri Dec 15 14:58:19 GMT 2023 , Edited by admin on Fri Dec 15 14:58:19 GMT 2023
|
PRIMARY | |||
|
3360
Created by
admin on Fri Dec 15 14:58:19 GMT 2023 , Edited by admin on Fri Dec 15 14:58:19 GMT 2023
|
PRIMARY | |||
|
CHEMBL1418176
Created by
admin on Fri Dec 15 14:58:19 GMT 2023 , Edited by admin on Fri Dec 15 14:58:19 GMT 2023
|
PRIMARY | |||
|
COZ1R7EOCC
Created by
admin on Fri Dec 15 14:58:19 GMT 2023 , Edited by admin on Fri Dec 15 14:58:19 GMT 2023
|
PRIMARY | |||
|
METHANDROSTENOLONE
Created by
admin on Fri Dec 15 14:58:19 GMT 2023 , Edited by admin on Fri Dec 15 14:58:19 GMT 2023
|
PRIMARY | |||
|
D008696
Created by
admin on Fri Dec 15 14:58:19 GMT 2023 , Edited by admin on Fri Dec 15 14:58:19 GMT 2023
|
PRIMARY | |||
|
100000089098
Created by
admin on Fri Dec 15 14:58:19 GMT 2023 , Edited by admin on Fri Dec 15 14:58:19 GMT 2023
|
PRIMARY | |||
|
983
Created by
admin on Fri Dec 15 14:58:19 GMT 2023 , Edited by admin on Fri Dec 15 14:58:19 GMT 2023
|
PRIMARY | |||
|
m7293
Created by
admin on Fri Dec 15 14:58:19 GMT 2023 , Edited by admin on Fri Dec 15 14:58:19 GMT 2023
|
PRIMARY | Merck Index | ||
|
DB13586
Created by
admin on Fri Dec 15 14:58:19 GMT 2023 , Edited by admin on Fri Dec 15 14:58:19 GMT 2023
|
PRIMARY | |||
|
C87589
Created by
admin on Fri Dec 15 14:58:19 GMT 2023 , Edited by admin on Fri Dec 15 14:58:19 GMT 2023
|
PRIMARY | |||
|
DTXSID2023276
Created by
admin on Fri Dec 15 14:58:19 GMT 2023 , Edited by admin on Fri Dec 15 14:58:19 GMT 2023
|
PRIMARY | |||
|
SUB08812MIG
Created by
admin on Fri Dec 15 14:58:19 GMT 2023 , Edited by admin on Fri Dec 15 14:58:19 GMT 2023
|
PRIMARY | |||
|
6300
Created by
admin on Fri Dec 15 14:58:19 GMT 2023 , Edited by admin on Fri Dec 15 14:58:19 GMT 2023
|
PRIMARY | |||
|
42722
Created by
admin on Fri Dec 15 14:58:19 GMT 2023 , Edited by admin on Fri Dec 15 14:58:19 GMT 2023
|
PRIMARY | |||
|
6818
Created by
admin on Fri Dec 15 14:58:19 GMT 2023 , Edited by admin on Fri Dec 15 14:58:19 GMT 2023
|
PRIMARY | RxNorm | ||
|
200-787-2
Created by
admin on Fri Dec 15 14:58:19 GMT 2023 , Edited by admin on Fri Dec 15 14:58:19 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
METABOLITE -> PARENT |
IN-VIVO
URINE
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |